Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

Jerry S. Wolinsky, Ponnada A. Narayana, Paul O'Connor, Patricia K. Coyle, Corey Ford, Kenneth Johnson, Aaron Miller, Lillian Pardo, Shaul Kadosh, David Ladkani, Lorne Kastrukoff, Pierre Duquette, Mark Freedman, Marc Debouverie, Catherine Lubetski, Gilles Edan, Etienne Roullet, Christian Confavreux, Alan Thompson, Lance BlumhardtStanley Hawkins, Thomas Scott, Daniel Wynn, Joanna Cooper, Stephen Thurston, Stanton Elias, Clyde Markowitz, David Mattson, John Noseworthy, Elizabeth Shuster, Jonathan Carter, Fred Lublin, William Stuart, Michael Kaufman, Gary Birnbaum, Kottil Rammohan, Ruth Whitham, Cornelia Mihai, Steven Greenberg, Craig Smith, Mark Agius, Stan Van Den Noort, Lawrence Myers, James Nelson, Douglas Goodin, Barry Arnason, Khurram Bashir, Sharon Lynch, Stephen Kamin, William Sheremata, Galen Mitchell, Andrew Goodman, Norman Kachuck, Peter Dunne, J. William Lindsey, Elliot Frohman, James Bowen, Benjamin Brooks, John Rose, Harold Moses, Douglas Jeffrey, Ann Cross, Robert Lisak, Tim Vollmer, Jack Antel, Gary Cutter, Luanne Metz, Henry McFarland, Steven Reingold, Fred D. Lublin, Irina Vainrub, Lucie Lambert, Fengwei Zhong, Jeff Rasmituth, Saria Momin, Rivka Kreitman, Galia Shifroni, Irit Pinchasi, Yafit Stark

Research output: Contribution to journal › Article › peer-review

348 Scopus citations

Fingerprint

Dive into the research topics of 'Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences